STAT

MARCH 31, 2023

Amid treaty talks to create equitable access to medical products during pandemics, the European Union has proposed pricing language that may put the pharmaceutical industry and advocacy groups on a collision course.

Drug Pricing 245

Drug Pricing Vaccines 245

STAT

AUGUST 22, 2023

The Food and Drug Administration approved a Pfizer vaccine that aims to protect newborns against RSV by vaccinating pregnant people, STAT tells us. The vaccine, marketed as Abrysvo, previously won approval for adults over the age of 60.

Vaccines 246

Vaccines Drug Pricing Diabetes Pharmaceutical Companies 246

STAT

OCTOBER 5, 2023

Damian here with a rare look at a biotech in collapse, Moderna’s ambitious future in vaccines, and what looks like a massive missed opportunity. Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, all. Read the rest…

Vaccines 314

Vaccines Drug Pricing Drug Development 314

STAT

FEBRUARY 14, 2024

We see a new startup emerge that aims to compete with Vertex Pharmaceuticals, and learn of Phase 1 results for Replicate’s srRNA rabies vaccine. Today, we discuss how Biogen’s missed the mark with Leqembi, but how it’s also not exactly a surprise. Read the rest…

Vaccines 275

Vaccines Drug Pricing Drug Development 275

STAT

OCTOBER 3, 2022

… Moderna refused to hand over to China the core intellectual property behind the development of its Covid-19 vaccine, leading to a collapse in negotiations on its sale there , The Financial Times reports. Moderna was pressed to take the former option. Continue to STAT+ to read the full story…

Drug Pricing 246

Drug Pricing Vaccines 246

STAT

JULY 25, 2023

A hearing began in a South Africa court on Tuesday to determine whether the government overpaid for Covid-19 vaccines, an allegation made by advocacy groups who contend that a lack of transparency may have masked pharmaceutical profits at the public’s expense. The contracts, however, have never been publicly disclosed.

Vaccines 246

Vaccines Drug Pricing 246

STAT

DECEMBER 20, 2023

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Today, we get into why Amy Abernethy is leaving Verily, and why the ongoing reckoning with AI doesn’t necessarily need the voice of Google to chime in.

Vaccines 363

Vaccines Drug Pricing Drug Development 363

STAT

JUNE 6, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning. Today, we discuss how psychedelics companies are responding to the negative ad comm vote on Lykos’ therapy, results of Zepbound in MASH, and the fate of Novovax this fall.

Vaccines 348

Vaccines Drug Pricing Drug Development 348

STAT

APRIL 9, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with an update on the biotech market, a look at the future of genome editing, and the evolving definition of “insider trading.” ” Read the rest…

Vaccines 314

Vaccines Drug Pricing Drug Development 314

STAT

DECEMBER 13, 2022

lawmakers wrote Pfizer chief executive officer Albert Bourla that he should “back off” from plans to charge Americans up to $130 for the company’s Covid-19 vaccine, a move they described as “pure and deadly greed.” argued the planned price tag is nearly four times the current $30 price paid by the U.S.

Vaccines 246

Vaccines Drug Pricing 246

STAT

JANUARY 9, 2023

Moderna disclosed Monday that it plans to price its Covid-19 vaccine at anywhere from $110 to $130 per dose when the company pivots from a focus on government contracts to commercial distribution efforts. The timing was not disclosed, but the company is holding talks with hospitals, pharmacy chains and pharmacy benefit managers.

Vaccines 267

Vaccines Hospitals Drug Pricing 267

STAT

JANUARY 30, 2023

lawmakers have asked Pfizer not to raise the price of its Covid-19 vaccine, citing concerns such a move could strain the U.K. In a letter to Pfizer chief executive officer Albert Bourla, the lawmakers noted the company plans to raise the price of its shot to $110 to $130 a dose in the U.S. Several U.K.

Vaccines 246

Vaccines Drug Pricing 246

STAT

MAY 23, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning. Wall Street had a big reaction to H5N1 bird flu news yesterday. Was it warranted? We’ll discuss that today. Read the rest…

Vaccines 338

Vaccines Drug Pricing Drug Development 338

STAT

OCTOBER 27, 2022

Our colleague Sarah Owermohle joins us to discuss how pandemic shutdowns, Covid-19 vaccines, and the prospect of arresting Anthony Fauci have become campaign rallying cries in midterm elections. Read the rest…

Drug Pricing 246

Drug Pricing Vaccines 246

STAT

NOVEMBER 3, 2023

There’s potential that a stem cell infusion from kidney donors might help prevent organ rejection — allowing patients to perhaps wean from immunosuppressive drugs. Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox.

Vaccines 297

Vaccines Drug Pricing Drug Development 297

STAT

JUNE 10, 2024

Lots on vaccines this morning: Moderna says its combination shot for Covid and flu works well, and might help improve uptake in the broader population. And the FDA just cleared GSK’s RSV vaccine for younger at-risk adults. Want to stay on top of the science and politics driving biotech today?  Read the rest…

Vaccines 297

Vaccines Drug Pricing Drug Development 297

STAT

JUNE 25, 2023

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Drug Pricing 246

Drug Pricing Vaccines 246

STAT

FEBRUARY 1, 2024

Biotech can’t shake the Fed The XBI, a closely watched index of biotech stocks, turned red for the year yesterday, and not because of a clinical disappointment, a drug pricing scandal, or an M&A rumor that came to nothing. In 2024, as in 2023, the industry’s fate seems inextricable from interest rates.

Drug Pricing 326

Drug Pricing Vaccines Communication Drug Development 326

STAT

AUGUST 15, 2024

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Good morning. Big news this morning, so let’s get straight into it. Read the rest…

Vaccines 303

Vaccines Drug Pricing Drug Development 303

STAT

OCTOBER 11, 2022

… Michelle McMurry-Heath, one of the most prominent faces of the drug industry in Washington, resigned as head of the Biotechnology Innovation Organization following disagreements with some board members , The Wall Street Journal reports. government.

Vaccines 244

Vaccines Drug Pricing 244

STAT

OCTOBER 8, 2024

The trade group, however, insisted the FDA “acted to benefit special interests, raise drug prices and deprive much of the public of access to a needed medicine.” A group of doctors and medical practices claimed they overpaid for the vaccine, which was the only mumps shot in the U.S. ” A U.S.

Compounding 265

Compounding Compounding Pharmacies Vaccines Immunity 265

STAT

MARCH 3, 2025

Also, lots of updates on vaccines, and Ginkgo starts subleasing its lab space.  Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Today, we bid adieu to NIH luminary Francis Collins.   Read the rest…

Vaccines 168

Vaccines Drug Pricing Drug Development 168

STAT

MARCH 25, 2024

We also examine how Covid-19 vaccine makers are faring today, and more. Today, we discuss the implications of the Supreme Court’s forthcoming mifepristone evaluation on the FDA and the biopharma industry. Read the rest…

Vaccines 290

Vaccines Drug Pricing Drug Development 290

STAT

FEBRUARY 13, 2024

Today, some amazing intel on Merck’s Ebola vaccine: Turns out, it can reduce risk of death, even after a person has been infected. Also, investors bet on another obesity drug — this time from BioAge, which is combining Zepbound with a pill that keeps muscle wasting at bay. It’s Meghana.

Vaccines 282

Vaccines Drug Pricing Drug Development 282

STAT

MAY 20, 2024

Today, we talk about how Bernie Sanders might be hitting a wall with the drug industry, see a glimmer of potential for HIV vaccines, and introduce a new Monday fundraising feature.   Sign up  to get our biotech newsletter in your inbox. Read the rest…

Vaccines 269

Vaccines Drug Pricing Drug Development 269

STAT

FEBRUARY 22, 2024

Damian here with an update on the plight of the  other  Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom. Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, all.

Vaccines 289

Vaccines Drug Pricing Drug Development 289

STAT

MAY 20, 2024

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing.

Diabetes 350

Diabetes Pharmaceutical Companies Pharmaceutical Companies Vaccines 350

STAT

JANUARY 16, 2024

Today, we talk a lot about regulatory policy — for flu vaccines and for physicians.   Sign up  to get our biotech newsletter in your inbox. Hope you had a restful and reflective long weekend.

Vaccines 275

Vaccines Drug Pricing Drug Development 275

STAT

MARCH 22, 2023

WASHINGTON — Moderna CEO Stéphane Bancel and Senate health committee Chair Bernie Sanders shook hands amicably before Wednesday’s hearing examining the company’s vaccine pricing strategy began. That’s about where the goodwill ended between the two. Read the rest…

Vaccines 257

Vaccines Drug Pricing 257

STAT

JANUARY 17, 2023

In another bid to widen access to its medical products, Pfizer plans to provide roughly 500 medicines and vaccines — many of which are no longer protected by patents — at not-for-profit prices t0 45 mostly low-income countries.

Vaccines 267

Vaccines Drug Pricing 267

STAT

DECEMBER 8, 2023

Today, we talk about the much-awaited CRISPR-based drug Casgevy, discuss the new Gavi initiative that plans to dramatically ramp up vaccine manufacturing in Africa, and more.   Sign up  to get our biotech newsletter in your inbox. Have a nice weekend! Read the rest…

Vaccines 246

Vaccines Drug Pricing Drug Development 246

STAT

DECEMBER 15, 2022

AbbVie, which for years has fought off competition for its blockbuster autoimmune drug Humira — the world’s top-selling medicine before Pfizer’s Covid-19 vaccine hit the market — has been the target of congressional hearings and legislation aimed at so-called patent thickets that can stall rival products.

Vaccines 303

Vaccines Drug Pricing 303

STAT

JULY 6, 2023

Advertisements eviscerating and glorifying pharmacy benefit managers have been around for years, but have intensified over the past three months as Congress scrutinizes the role these middlemen play in shaping high prescription drug prices , STAT tells us.

Drug Pricing 233

Drug Pricing Vaccines Diabetes Pharmaceutical Companies 233

Pharmaceutical Technology

SEPTEMBER 15, 2022

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccines 108

Vaccines Drug Pricing Biosimilars Documentation 108

STAT

NOVEMBER 13, 2023

We also learn about a new initiative to try and prevent gonorrhea spread with a meningitis vaccine. Lots of news on the cardiovascular front this morning: We discuss Novo Nordisk’s plans in heart disease, and Verve’s gene editing therapy for familial hypercholesterolemia. Read the rest…

Vaccines 267

Vaccines Drug Pricing Drug Development 267

STAT

JUNE 21, 2024

Enjoy, and see you soon… In a surprise move, Doctors Without Borders is closing down its access-to-medicines campaign, which has been credited with ensuring needed drugs and vaccines have been made available to countless patients in low-income countries around the world , STAT reports.

Vaccines 266

Vaccines Drug Pricing Drug Development 266

STAT

DECEMBER 13, 2024

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 billion, the highest level since tracking of funding began in 2005 and 20% more than what was seen in 2022.

Pharmaceutical Companies 257

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Pricing 257